John W Apolzan1, Elizabeth M Venditti2, Sharon L Edelstein3, William C Knowler4, Dana Dabelea5, Edward J Boyko6, Xavier Pi-Sunyer7, Rita R Kalyani8, Paul W Franks9, Preethi Srikanthan10, Kishore M Gadde1. 1. Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana (J.W.A., K.M.G.). 2. Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (E.M.V.). 3. George Washington University Biostatistics Center, Rockville, Maryland (S.L.E.). 4. National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona (W.C.K.). 5. Colorado School of Public Health, Aurora, Colorado (D.D.). 6. Seattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, Washington (E.J.B.). 7. Columbia University College of Physicians and Surgeons, New York, New York (X.P.). 8. Johns Hopkins University School of Medicine, Baltimore, Maryland (R.R.K.). 9. Lund University Diabetes Centre, Skåne University Hospital, Malmö, Sweden (P.W.F.). 10. University of California, Los Angeles, Los Angeles, California (P.S.).
Abstract
Background: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management. Objective: To identify some predictors of LTWL. Design: The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. (ClinicalTrials.gov: NCT00004992 and NCT00038727). Setting: 27 DPP and DPPOS clinics. Participants: Of the 3234 randomly assigned participants, 1066 lost at least 5% of baseline weight in the first year and were followed for 15 years. Measurements: Treatment assignment, personal characteristics, and weight. Results: After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group had lost at least 5% of their weight. After the masked treatment phase ended, the mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% (95% CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. Independent predictors of LTWL included greater weight loss in the first year in all groups, older age and continued metformin use in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group. Limitation: Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1. Conclusion: Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance. Primary Funding Source: National Institutes of Health.
RCT Entities:
Background: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management. Objective: To identify some predictors of LTWL. Design: The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. (ClinicalTrials.gov: NCT00004992 and NCT00038727). Setting: 27 DPP and DPPOS clinics. Participants: Of the 3234 randomly assigned participants, 1066 lost at least 5% of baseline weight in the first year and were followed for 15 years. Measurements: Treatment assignment, personal characteristics, and weight. Results: After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group had lost at least 5% of their weight. After the masked treatment phase ended, the mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% (95% CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. Independent predictors of LTWL included greater weight loss in the first year in all groups, older age and continued metformin use in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group. Limitation: Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1. Conclusion: Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance. Primary Funding Source: National Institutes of Health.
Authors: Richard F Hamman; Rena R Wing; Sharon L Edelstein; John M Lachin; George A Bray; Linda Delahanty; Mary Hoskin; Andrea M Kriska; Elizabeth J Mayer-Davis; Xavier Pi-Sunyer; Judith Regensteiner; Beth Venditti; Judith Wylie-Rosett Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Rena R Wing; Richard F Hamman; George A Bray; Linda Delahanty; Sharon L Edelstein; James O Hill; Edward S Horton; Mary A Hoskin; Andrea Kriska; John Lachin; Elizabeth J Mayer-Davis; Xavier Pi-Sunyer; Judith G Regensteiner; Beth Venditti; Judith Wylie-Rosett Journal: Obes Res Date: 2004-09
Authors: G Paolisso; L Amato; R Eccellente; A Gambardella; M R Tagliamonte; G Varricchio; C Carella; D Giugliano; F D'Onofrio Journal: Eur J Clin Invest Date: 1998-06 Impact factor: 4.686
Authors: Ariana M Chao; Thomas A Wadden; Robert I Berkowitz; George Blackburn; Paula Bolin; Jeanne M Clark; Mace Coday; Jeffrey M Curtis; Linda M Delahanty; Gareth R Dutton; Mary Evans; Linda J Ewing; John P Foreyt; Linda J Gay; Edward W Gregg; Helen P Hazuda; James O Hill; Edward S Horton; Denise K Houston; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; William C Knowler; Anne Kure; Katherine L Michalski; Maria G Montez; Rebecca H Neiberg; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Bruce Redmon; W Jack Rejeski; Helmut Steinburg; Martha Walker; Donald A Williamson; Rena R Wing; Holly Wyatt; Susan Z Yanovski; Ping Zhang Journal: Obesity (Silver Spring) Date: 2020-05 Impact factor: 5.002
Authors: Elizabeth M Venditti; Marsha D Marcus; Rachel G Miller; Vincent C Arena; Susan L Greenspan; Bonny Rockette-Wagner Journal: J Gerontol A Biol Sci Med Sci Date: 2021-01-18 Impact factor: 6.053
Authors: Wendy K Chung; Karel Erion; Jose C Florez; Andrew T Hattersley; Marie-France Hivert; Christine G Lee; Mark I McCarthy; John J Nolan; Jill M Norris; Ewan R Pearson; Louis Philipson; Allison T McElvaine; William T Cefalu; Stephen S Rich; Paul W Franks Journal: Diabetologia Date: 2020-09 Impact factor: 10.122
Authors: Debra L Waters; Lina Aguirre; Burke Gurney; David R Sinacore; Kenneth Fowler; Giulia Gregori; Reina Armamento-Villareal; Clifford Qualls; Dennis T Villareal Journal: J Gerontol A Biol Sci Med Sci Date: 2022-01-07 Impact factor: 6.053
Authors: Megan O Bensignor; Eric M Bomberg; Carolyn T Bramante; T V S Divyalasya; Paula M Hale; Chethana K Ramesh; Kyle D Rudser; Aaron S Kelly Journal: Pediatr Obes Date: 2021-02-25 Impact factor: 3.910